Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2022-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ecdbc88d68c44d1b846e65a765b81748 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ye Peng |e author |
| 700 | 1 | 0 | |a Xiaohui Zeng |e author |
| 700 | 1 | 0 | |a Liubao Peng |e author |
| 700 | 1 | 0 | |a Qiao Liu |e author |
| 700 | 1 | 0 | |a Lidan Yi |e author |
| 700 | 1 | 0 | |a Xia Luo |e author |
| 700 | 1 | 0 | |a Sini Li |e author |
| 700 | 1 | 0 | |a Liting Wang |e author |
| 700 | 1 | 0 | |a Shuxia Qin |e author |
| 700 | 1 | 0 | |a Xiaomin Wan |e author |
| 700 | 1 | 0 | |a Chongqing Tan |e author |
| 245 | 0 | 0 | |a Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis |
| 260 | |b Frontiers Media S.A., |c 2022-02-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2022.778505 | ||
| 520 | |a Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar as a first-line treatment for unresectable hepatocellular carcinoma from the Chinese perspective of healthcare system.Materials and methods: A Markov model with three mutual health states was constructed to evaluate the economic outcome of sintilimab plus bevacizumab biosimilar. The model cycle was 21 days, and the simulation time horizon was a lifetime. The output parameters of the model were the total cost, life-year (LY), quality-adjusted LY (QALY), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses were conducted to assess the robustness of the results.Results: The base-case results found that sintilimab plus bevacizumab biosimilar provided an improvement of 1.27 QALYs and 1.84 LYs compared with sorafenib, and the ICER was $23,352/QALY. The hazard ratio for OS had the greatest influence on the ICER. The probability of sintilimab plus bevacizumab biosimilar was 85% at willingness-to-pay thresholds of $30,552/QALY.Conclusion: The findings of this analysis suggested that sintilimab plus bevacizumab biosimilar was a cost-effective first-line therapy for patients with unresectable hepatocellular carcinoma. | ||
| 546 | |a EN | ||
| 690 | |a sintilimab | ||
| 690 | |a bevacizumab biosimilar | ||
| 690 | |a cost-effectiveness | ||
| 690 | |a hepatocellular carcinoma | ||
| 690 | |a markov model | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.778505/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ecdbc88d68c44d1b846e65a765b81748 |z Connect to this object online. |